Paradigm Biocapital Advisors LP T Scan Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
91Shares Held
42.3MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.22MShares$13.2 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$12.6 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$11.3 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$11.1 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$7.56 Million0.47% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $47.9M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...